Peptimmune Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Liquidation

Peptimmune General Information

Description

Developer of peptide and peptide-copolymer therapeutics for the treatment of CNS and autoimmune disorders. The company provides PI-2301 peptide copolymer for the treatment of multiple sclerosis; and DEEP vaccines for viral, bacterial, and parasitic infectious diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 64 Sidney Street
  • Suite 380
  • Cambridge, MA 02139
  • United States
Primary Industry
Pharmaceuticals
Vertical(s)
Corporate Office
  • 64 Sidney Street
  • Suite 380
  • Cambridge, MA 02139
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Peptimmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Bankruptcy: Liquidation 23-Mar-2011 Completed Bankruptcy: Liquidation
4. Later Stage VC (Series D) 17-Jan-2008 Completed Generating Revenue
3. Later Stage VC (Series C) 15-Jul-2005 Completed Generating Revenue
2. Early Stage VC (Series B) 04-Mar-2003 $41.2M $46.7M Completed Generating Revenue
1. Early Stage VC (Series A) 19-Jan-2002 $5.5M $5.5M Completed Product Development
To view Peptimmune’s complete valuation and funding history, request access »

Peptimmune Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D
Series C
Series B 25,242,857 $0.010000 6% $1.05 $1.05 1x $172.72 3.84%
Series A 5,500,000 $0.010000 6% $1 $1 1x $126.82 1.08%
To view Peptimmune’s complete cap table history, request access »

Peptimmune Patents

Peptimmune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2011063043-A1 Methods for improving the design, bioavailability, and efficacy of directed sequence polymer compositions via serum protein-based detection of directed sequence polymer compositions Inactive 17-Nov-2009
WO-2011063045-A1 Methods for improving the design, bioavailability, and efficacy of random sequence polymer compositions via serum protein-based detection of random sequence polymer compositions Inactive 17-Nov-2009
WO-2009128948-A1 Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders Inactive 17-Apr-2008
WO-2009075854-A2 Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods Inactive 10-Dec-2007
WO-2009075854-A3 Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods Inactive 10-Dec-2007 A61K38/16
To view Peptimmune’s complete patent history, request access »

Peptimmune Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Peptimmune FAQs

  • When was Peptimmune founded?

    Peptimmune was founded in 2002.

  • Where is Peptimmune headquartered?

    Peptimmune is headquartered in Cambridge, MA.

  • What is the size of Peptimmune?

    Peptimmune has 5 total employees.

  • What industry is Peptimmune in?

    Peptimmune’s primary industry is Pharmaceuticals.

  • Is Peptimmune a private or public company?

    Peptimmune is a Private company.

  • What is Peptimmune’s current revenue?

    The current revenue for Peptimmune is .

  • How much funding has Peptimmune raised over time?

    Peptimmune has raised $90.5M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process